Vogenx raised $84.4M from a $93.4M IPO in August 2026 to strengthen its balance sheet with $82.1M in liquidity and initiated its EMERGE clinical trial for mizagliflozin in post-bariatric hypoglycemia.
Vogenx raised $84.4M from a $93.4M IPO in August 2026 to strengthen its balance sheet with $82.1M in liquidity and initiated its EMERGE clinical trial for mizagliflozin in post-bariatric hypoglycemia.